Limits...
Diagnostic Utility of Caveolin-1 and MOC-31 in Distinguishing Chromophobe Renal Cell Carcinoma from Renal Oncocytoma.

Lee HW, Lee EH, Lee CH, Chang HK, Rha SH - Korean J Urol (2011)

Bottom Line: Renal tumors consist of heterogeneous groups that frequently show complex and overlapping morphology, thus making it difficult to make a correct diagnosis.These should be distinguished by differences in their behavior and clinical outcome.In addition, clear cell RCC was also significantly different from oncocytoma in the expression of caveolin-1 (p<0.001) and was significantly different from chromophobe RCC in the expression of MOC-31 (p<0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.

ABSTRACT

Purpose: Renal tumors consist of heterogeneous groups that frequently show complex and overlapping morphology, thus making it difficult to make a correct diagnosis. One of the most problematic differential diagnoses is to distinguish chromophobe renal cell carcinoma (RCC) from oncocytoma. These should be distinguished by differences in their behavior and clinical outcome. Our study was performed to identify whether caveolin-1 and MOC-31 are useful immunohistochemical markers for differentiating chromophobe RCC from oncocytoma.

Materials and methods: We selected 23 chromophobe RCCs, 8 oncocytomas, and 25 clear cell RCCs and performed immunohistochemical staining for caveolin-1 and MOC-31.

Results: Caveolin-1 was positive in 20 (87%) of 23 chromophobe RCCs, 0 of 8 oncocytomas, and 21 (84%) of 25 clear cell RCCs. MOC-31 was positive in 22 (96%) of 23 chromophobe RCCs, 2 (25%) of 8 oncocytomas, and 14 (56%) of 25 clear cell RCCs. There was a statistically significant difference in the expression of caveolin-1 and MOC-31 between chromophobe RCC and oncocytoma (p<0.001). In addition, clear cell RCC was also significantly different from oncocytoma in the expression of caveolin-1 (p<0.001) and was significantly different from chromophobe RCC in the expression of MOC-31 (p<0.001).

Conclusions: Caveolin-1 and MOC-31 can be useful markers in the differential diagnosis of chromophobe RCC, oncocytoma, and clear cell RCC.

No MeSH data available.


Related in: MedlinePlus

Expression of MOC-31 in oncocytoma with tubular differentiation. In a few cases of oncocytomas, MOC-31 is expressed in the tumor cells showing tubular differentiation but not solid or trabecular nests.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3045726&req=5

Figure 5: Expression of MOC-31 in oncocytoma with tubular differentiation. In a few cases of oncocytomas, MOC-31 is expressed in the tumor cells showing tubular differentiation but not solid or trabecular nests.

Mentions: In oncocytomas, MOC-31 was negative in 6 of 8 cases and diffuse positive in the other 2 cases (25%) (Fig. 4B). Three of the six negative cases expressed MOC-31 in less than 10% of the tumor cells, and the other three cases showed no staining. In the former three cases, MOC-31 was characteristically expressed in the tumor cells showing tubular structures but not solid nests or trabecular structures. In addition, two oncocytomas showing diffuse expression of MOC-31 were composed of predominantly tubular structures, and solid or trabecular structures were only a minor portion. MOC-31 was expressed in such tubular structures rather than in solid or trabecular structures (Fig. 5).


Diagnostic Utility of Caveolin-1 and MOC-31 in Distinguishing Chromophobe Renal Cell Carcinoma from Renal Oncocytoma.

Lee HW, Lee EH, Lee CH, Chang HK, Rha SH - Korean J Urol (2011)

Expression of MOC-31 in oncocytoma with tubular differentiation. In a few cases of oncocytomas, MOC-31 is expressed in the tumor cells showing tubular differentiation but not solid or trabecular nests.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3045726&req=5

Figure 5: Expression of MOC-31 in oncocytoma with tubular differentiation. In a few cases of oncocytomas, MOC-31 is expressed in the tumor cells showing tubular differentiation but not solid or trabecular nests.
Mentions: In oncocytomas, MOC-31 was negative in 6 of 8 cases and diffuse positive in the other 2 cases (25%) (Fig. 4B). Three of the six negative cases expressed MOC-31 in less than 10% of the tumor cells, and the other three cases showed no staining. In the former three cases, MOC-31 was characteristically expressed in the tumor cells showing tubular structures but not solid nests or trabecular structures. In addition, two oncocytomas showing diffuse expression of MOC-31 were composed of predominantly tubular structures, and solid or trabecular structures were only a minor portion. MOC-31 was expressed in such tubular structures rather than in solid or trabecular structures (Fig. 5).

Bottom Line: Renal tumors consist of heterogeneous groups that frequently show complex and overlapping morphology, thus making it difficult to make a correct diagnosis.These should be distinguished by differences in their behavior and clinical outcome.In addition, clear cell RCC was also significantly different from oncocytoma in the expression of caveolin-1 (p<0.001) and was significantly different from chromophobe RCC in the expression of MOC-31 (p<0.001).

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.

ABSTRACT

Purpose: Renal tumors consist of heterogeneous groups that frequently show complex and overlapping morphology, thus making it difficult to make a correct diagnosis. One of the most problematic differential diagnoses is to distinguish chromophobe renal cell carcinoma (RCC) from oncocytoma. These should be distinguished by differences in their behavior and clinical outcome. Our study was performed to identify whether caveolin-1 and MOC-31 are useful immunohistochemical markers for differentiating chromophobe RCC from oncocytoma.

Materials and methods: We selected 23 chromophobe RCCs, 8 oncocytomas, and 25 clear cell RCCs and performed immunohistochemical staining for caveolin-1 and MOC-31.

Results: Caveolin-1 was positive in 20 (87%) of 23 chromophobe RCCs, 0 of 8 oncocytomas, and 21 (84%) of 25 clear cell RCCs. MOC-31 was positive in 22 (96%) of 23 chromophobe RCCs, 2 (25%) of 8 oncocytomas, and 14 (56%) of 25 clear cell RCCs. There was a statistically significant difference in the expression of caveolin-1 and MOC-31 between chromophobe RCC and oncocytoma (p<0.001). In addition, clear cell RCC was also significantly different from oncocytoma in the expression of caveolin-1 (p<0.001) and was significantly different from chromophobe RCC in the expression of MOC-31 (p<0.001).

Conclusions: Caveolin-1 and MOC-31 can be useful markers in the differential diagnosis of chromophobe RCC, oncocytoma, and clear cell RCC.

No MeSH data available.


Related in: MedlinePlus